Clinical trials
Geographic Atrophy From Age-related Macular Degeneration clinical trials
Below are recruiting geographic atrophy from age-related macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 45 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07770828RecruitingPhase 3
Gene therapy for advanced dry age-related macular degeneration
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
McAllen, TexasAges 55 years+ - NCT06541704RecruitingPhase 3
Study of pozelimab with cemdisiran for geographic atrophy
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
Chandler, ArizonaAges 50–85 - NCT06662162Recruiting
Microcurrent therapy for dry age-related macular degeneration
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
Poway, CaliforniaAges 60 years+ - NCT06619405Recruiting
Eye Function Test for Age-Related Macular Degeneration
This study tests a quick, noninvasive eye test that measures how well you see in the dark, which can be an early sign of dry AMD. Researchers want to see if the test relates to everyday tasks like reading or driving at night.
Durham, North CarolinaAges 50–89 - NCT06765980RecruitingPhase 1/Phase 2
Study of KRIYA-825 for geographic atrophy in age-related macular degeneration
This trial tests an experimental drug called KRIYA-825 (also known as VV-14295) for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes vision loss. The study aims to see if the treatment is safe and can help slow the progression of the disease.
Erie, PennsylvaniaAges 55–80 - NCT05562947RecruitingPhase 3
Ranibizumab port implant for wet macular degeneration in Chinese adults
This Phase 3 study tests whether a small eye implant that delivers medicine on a schedule (the port delivery system) with ranibizumab works better and safely in people with wet age-related macular degeneration. It’s designed for patients who have already been treated recently with anti-VEGF injections and need continued control.
BeijingAges 50 years+ - NCT07189169RecruitingPhase 3
Testing QA108 for intermediate AMD
This trial tests an investigational medicine (QA108) for people with intermediate age-related macular degeneration (AMD). It aims to slow or prevent progression of the disease by treating the deposits (drusen) in the center of the retina.
BeijingAges 45–85 - NCT07441642RecruitingPhase 2
Testing FWY003 eye drops for geographic atrophy (dry AMD)
This trial tests a new eye drop called FWY003 against a placebo (an inactive drop) to see if it can slow the progression of geographic atrophy (the dry form of age-related macular degeneration). It may help people who have moderate vision loss from this condition.
Huntington Beach, CaliforniaAges 50 years+ - NCT07582042Recruiting
Vision testing in geographic atrophy treated with pegcetacoplan
This study tests a specialized vision-testing method in people with geographic atrophy (a type of dry age-related macular degeneration) who are already receiving pegcetacoplan injections. The goal is to better understand how this treatment affects vision in different parts of the eye.
Salt Lake City, UtahAges 65–90 - NCT07215390RecruitingPhase 2
Study of APL-3007 plus Syfovre for geographic atrophy
This trial tests whether a new drug called APL-3007, when added to your current Syfovre treatment, can slow the progression of geographic atrophy (an advanced form of dry age-related macular degeneration). It's for people who have already been on Syfovre for at least 6 months.
Gilbert, ArizonaAges 60 years+ - NCT07392255RecruitingPhase 1/Phase 2
Testing CTx001 for geographic atrophy (GA) in AMD
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
Carmel, IndianaAges 55 years+ - NCT06990269RecruitingPhase 2
Study of ADX-038 for geographic atrophy in dry AMD
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
Gilbert, ArizonaAges 60 years+ - NCT06165068RecruitingPhase 3
Antiplatelet and antioxidant drugs for dry AMD with drusen
This study tests whether antiplatelet drugs (like aspirin) and antioxidants can slow the growth of drusen (yellow deposits) in dry age-related macular degeneration (AMD). It may help prevent the disease from worsening.
Bangkok, DusitAges 50–85 - NCT07144137Recruiting
Observation study for geographic atrophy progression
This study observes how geographic atrophy (an advanced form of dry age-related macular degeneration) changes over a short period. If you have this condition in both eyes and meet certain vision and eye health criteria, you may be able to join this non-treatment study to help researchers learn more about the disease.
Mountain View, CaliforniaAges 55 years+ - NCT06659445RecruitingPhase 2
Study of ONL1204 for geographic atrophy in dry AMD
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Gilbert, ArizonaAges 55 years+ - NCT07482176RecruitingPhase 3
Gene therapy trial for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
Mesa, ArizonaAges 50 years+ - NCT03178149RecruitingPhase 1
Study of a new eye treatment for dry macular degeneration
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
Phoenix, ArizonaAges 50 years+ - NCT04292080RecruitingPhase 2
Tecfidera trial to slow worsening geographic atrophy
This Phase 2 study tests dimethyl fumarate (Tecfidera) to slow the growth of geographic atrophy, a form of age-related macular degeneration that affects central vision. You may be asked to take the study medicine and attend regular eye scans over about 2 years to see if it helps.
Créteil, Val De MarneAges 55–85 - NCT04339764RecruitingPhase 1/Phase 2
iPS cell eye transplant for dry macular degeneration
This early-phase study tests whether transplanting lab-made retinal cells from your own body can slow vision loss from geographic atrophy caused by dry age-related macular degeneration. It involves eye surgery and frequent follow-up to check safety and early signs of benefit.
Baltimore, MarylandAges 55–95 - NCT04504123RecruitingPhase 2
Doxycycline eye treatment for persistent wet macular degeneration fluid
This trial tests whether an “MMP-9 inhibitor” medicine given as doxycycline (a tetracycline-type antibiotic) can reduce persistent leaking and fluid in wet age-related macular degeneration. It may help people whose wet AMD is not fully controlled even after several anti-VEGF injections.
Iowa City, IowaAges 50–99 - NCT04739319Recruiting
Study of age-related macular degeneration changes
This study looks closely at how age-related macular degeneration (AMD) develops and changes over time by taking detailed eye measurements. It may help researchers better understand disease progression, especially for people who already have AMD.
East Melbourne, VictoriaAges 18 years+ - NCT04796545Recruiting
Implant study for late macular degeneration with cataracts
This post-market study looks at how well a telescope-like eye implant (NG SI IMT 3X) works for people with very advanced age-related macular degeneration that affects the center of vision, plus cataracts. The implant is placed in one eye, and you’ll get training to learn how to use it after surgery.
BrusselsAges 55 years+ - NCT04847635Recruiting
Laser test for aging-related macular spots under the retina
This trial studies a mild (“subthreshold”) laser treatment for reticular pseudodrusen (RPD) caused by age-related macular degeneration (AMD). If you qualify, the goal is to see whether the laser helps preserve or improve vision by targeting these specific eye changes.
GenovaAges 55 years+ - NCT07160179RecruitingPhase 1/Phase 2
Study of an eye injection for geographic atrophy
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
Carmel, IndianaAges 50 years+
Hear when a new Geographic Atrophy From Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for geographic atrophy from age-related macular degeneration?
- Yes. Clin2 currently lists 45 recruiting geographic atrophy from age-related macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a geographic atrophy from age-related macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a geographic atrophy from age-related macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.